IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4271 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
    A. General measures
    B. Topical treatment
    C. Oral Medications

 Article Access Statistics
    Viewed8838    
    Printed177    
    Emailed8    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal

 
HOW I MANAGE
Year : 2001  |  Volume : 67  |  Issue : 1  |  Page : 30

Post herpetic neuralgia (PHN)


Dept. of Dermatology, St. John's Medical College Hospital, Bangalore-560 034, India

Correspondence Address:
Dept. of Dermatology, St. John's Medical College Hospital, Bangalore-560 034, India



How to cite this article:
Abraham A. Post herpetic neuralgia (PHN). Indian J Dermatol Venereol Leprol 2001;67:30


How to cite this URL:
Abraham A. Post herpetic neuralgia (PHN). Indian J Dermatol Venereol Leprol [serial online] 2001 [cited 2019 Jun 15];67:30. Available from: http://www.ijdvl.com/text.asp?2001/67/1/30/8129


Dermatologists have to manage post herpetic neuralgia (PHN) because their patients expect them to deal with the pain after zoster and not only to treat the vesicular rash. It is ideal to manage the case if possible, without always referring to a neurologist.
I observe carefully any pain persisting after herpes zoster has healed and use the term post herpetic neuralgia when pain persists for more than 3 months after the rash heals.
There are 3 classical of PHN: constant burning pain (Amitryptiline group are the drugs of choice) intermittent stabbing pain (carbamazepine group are drugs of choice), and the combination/Allodynia type.
The risk factors for developing neuralgia are older age (infrequent <40 years age), greater acute pain severity, greater rash severity, sensory dysfunction in dermatome during zoster, painful prodrome pre­ceding and others including trigeminal distribution, psychosocial stress or fever. In patients with high risk and no other contraindication a short course of steroids during acute zoster helps to prevent PHN.
I manage severe cases of PHN in the following manner.

   A. General measures Top

The patient is asked to use loose cotton clothes especiallly for thoracic or lumbosacral zoster. A layer of Duoderm R or Cling film (used in the refrigerator to cover dishes) can be used as a protective separation between the skin and clothes. In severe cases cold compresses with an ice pack or a packet of frozen meat or vegetables from the freezer helps. Reassurance and explanation regarding the nature of disease are a vital part of treatment, as is psy­chotherapy.

   B. Topical treatment Top

Capsaicin invariably leads to a burning sensation and poor patient compliance. I have found EMLA under occlusion useful topically and look forward to the Lidoderm patch or gel (which is US FDA approved) becoming available locally. Another good advance in severe cases is the Fentanyl transdermal patch (Brand name DUROGESIC (25, 50 and 100 micrograms) Johnson & Johnson 25mcgr per hour sells for Rs. 1,150/- per patch. One patch lasts for only 72 hours. It is very useful in severe cases.

   C. Oral Medications Top

1. Antidepressants (tricyclic)
Though amitryptiline is the most widely used it has the side effects of sedation, anticholinergic action and postural hypotension which make it un­suitable for elderly patients. Nortryptiline is better tolerated (Sensival 25mg) and is a better choice. I start with 25mg at bedtime and build up by 25mg weekly to a maximum of 150mg/day or pain relief whichever is earlier.
2. Anticonvulsants
Carbamazepine or phenytoin is traditionally used, but adverse effects once again make patients non­compliant. Gabapentin is a better drug with excel­lent tolerability, improvement in pain ratings, sleep, mood and quality of life. It should be considered the first line treatment in those without depression. It is available as Gabantin, and is started at 100­300mg 3 times daily and built up at 300mg increments to a maximum of 3600mg/day or pain relief whichever is earlier. 

 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow